Hite Christopher

EVP & Chairman, PartneringRoyalty Pharma plc (RPRX) · full profile →Form 4 · filed Jul 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$7.3M
Net Open-Market Flow
-$7.3M
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2026Sell(S)97K$56.50$5.5M462K
Jun 30, 2026Sell(S)3K$57.10$146K459K
Jun 30, 2026Sell(S)29K$56.44$1.7M41K
Jun 30, 2026Sell(S)600$57.09$34K40K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001814238-26-000011) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about RPRX insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001814238-26-000011"
Ask your agent
Use Arkolith to summarize insider buying and selling at Royalty Pharma plc
over the last 90 days and cite the filings.